BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36135052)

  • 1. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.
    Shao B; Liu X; Li H; Song G; Di L; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J
    Curr Oncol; 2022 Aug; 29(9):6154-6166. PubMed ID: 36135052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
    Ding N; Pang J; Liu X; He X; Zhou W; Xie H; Feng J; Wang G; Tang J; Cao J; He L; He Y; Wang S; Xiao Z
    Breast Cancer Res; 2024 Jan; 26(1):9. PubMed ID: 38212845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of neutrophil-to-lymphocyte ratio in
    Shao B; Li H; Liu X; Song G; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J; Di L
    Ann Transl Med; 2023 Jan; 11(2):45. PubMed ID: 36819544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
    Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
    Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
    Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
    Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
    Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
    Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
    Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer.
    Yang J; Xu J; E Y; Sun T
    Cancer Med; 2019 Feb; 8(2):492-500. PubMed ID: 30632318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
    Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
    BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables.
    Ivars Rubio A; Yufera JC; de la Morena P; Fernández Sánchez A; Navarro Manzano E; García Garre E; García Martinez E; Marín Zafra G; Sánchez Cánovas M; García Torralba E; Ayala de la Peña F
    Sci Rep; 2019 Nov; 9(1):16979. PubMed ID: 31740715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.
    Bae SJ; Cha YJ; Yoon C; Kim D; Lee J; Park S; Cha C; Kim JY; Ahn SG; Park HS; Park S; Kim SI; Jeong J
    Sci Rep; 2020 Aug; 10(1):13078. PubMed ID: 32753659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
    Imamura M; Morimoto T; Egawa C; Fukui R; Bun A; Ozawa H; Miyagawa Y; Fujimoto Y; Higuchi T; Miyoshi Y
    Sci Rep; 2019 Feb; 9(1):1811. PubMed ID: 30755651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
    Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
    Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
    Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.